Skip to main content

Fiona Blackhall

Dr Fiona Blackhall is a Professor of Thoracic Oncology within the Institute of Cancer Studies, University of Manchester, UK, and a Consultant Medical Oncologist at The Christie Hospital, Manchester, UK. 

She has specific research interests in targeted therapies, personalized medicine, circulating biomarkers and small-cell lung cancer, and conducts clinical trials of new drugs for the treatment of lung cancer and translational research in clinically relevant biomarkers. 

She has served as co-chair of the translational subgroup of the European Thoracic Oncology Platform and on the scientific committee and the ESMO consensus guidelines panel for lung cancer for ESMO. She has been a faculty member and invited speaker for the ASCO Annual Meeting and IASLC.


Latest contributions from Fiona Blackhall

Cancer cells

17-05-2019 | Small-cell lung cancer | Highlight | News

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

04-01-2018 | Small-cell lung cancer | Conference report | Article

Progress in small cell lung cancer: an update from the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan

Advisory Board member Fiona Blackhall discusses the major new results in small cell lung cancer presented at the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan.

17-10-2017 | Fiona Blackhall | Article

Advisory board comment

Comment on: No survival, QoL gain for many EMA cancer drug approvals

New Content Item

26-07-2017 | Non-small-cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.